Growth Metrics

Genmab A (GMAB) Total Non-Current Liabilities (2023 - 2025)

Historic Total Non-Current Liabilities for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to $5.6 billion.

  • Genmab A's Total Non-Current Liabilities rose 95046.9% to $5.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.6 billion, marking a year-over-year increase of 95046.9%. This contributed to the annual value of $5.6 billion for FY2025, which is 95046.9% up from last year.
  • Genmab A's Total Non-Current Liabilities amounted to $5.6 billion in Q4 2025, which was up 95046.9% from $529.0 million recorded in Q3 2025.
  • In the past 5 years, Genmab A's Total Non-Current Liabilities registered a high of $5.6 billion during Q4 2025, and its lowest value of $177.0 million during Q4 2023.
  • For the 3-year period, Genmab A's Total Non-Current Liabilities averaged around $1.3 billion, with its median value being $533.0 million (2024).
  • In the last 5 years, Genmab A's Total Non-Current Liabilities skyrocketed by 20112.99% in 2024 and then soared by 95046.9% in 2025.
  • Quarter analysis of 3 years shows Genmab A's Total Non-Current Liabilities stood at $177.0 million in 2023, then soared by 201.13% to $533.0 million in 2024, then surged by 950.47% to $5.6 billion in 2025.
  • Its last three reported values are $5.6 billion in Q4 2025, $529.0 million for Q3 2025, and $533.0 million during Q2 2025.